Associated Genetic Biomarkers
FAN1 is altered in 2.24% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, melanoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in FAN1 are FAN1 Mutation (0.34%), FAN1 P788S (0.01%), FAN1 D873Tfs*17 (0.01%), FAN1 R12Gfs*45 (0.01%), and FAN1 V687I (0.01%) .
FAN1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FAN1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with FAN1 status in the inclusion eligibility criteria most commonly target breast carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is FAN1 Mutation .
Durvalumab, fulvestrant, and olaparib are the most frequent therapies in trials with FAN1 as an inclusion criteria .
Significance of FAN1 in Diseases
Breast Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.